All Pathways
Family MedicineManagement

GERD Evaluation & Management (ACG 2022)

GERD Evaluation & Management (ACG 2022): GERD Symptoms → Alarm Features? → EGD Referral → PPI Trial (8 Weeks) → Lifestyle Modifications.

Interactive Decision Tree

Mini Map

Algorithm Steps

  1. Start

    GERD Symptoms

    Heartburn, regurgitation ≥2x/week for ≥4 weeks

    1. Warning

      Alarm Features?

      Require EGD evaluation

      • Dysphagia or odynophagia
      • Unintended weight loss
      • GI bleeding or iron deficiency anemia
      • Recurrent vomiting
      • Age >60 with new-onset symptoms
      • Family history upper GI cancer
      1. Action

        EGD Referral

        Upper endoscopy indicated

        • Perform before empiric PPI if alarm features
        • Biopsy for Barrett's, eosinophilic esophagitis
        • Rule out malignancy, stricture
        • Can proceed with PPI after if no malignancy
        1. Action

          PPI Trial (8 Weeks)

          Standard-dose PPI once daily

          • Omeprazole 20mg, pantoprazole 40mg, esomeprazole 20-40mg
          • Take 30-60 min before breakfast
          • 8-week trial for adequate assessment
          • Lifestyle modifications concurrent
          1. Action

            Lifestyle Modifications

            Adjunctive measures

            • Weight loss if overweight
            • Elevate head of bed 6-8 inches
            • Avoid late meals (≥3h before bed)
            • Limit triggers: caffeine, alcohol, fatty foods
            • Smoking cessation
          2. Decision

            Response to PPI?

            Assess at 8 weeks

            1. Action

              PPI Responder

              Step-down approach

              • Taper to lowest effective dose
              • Try every-other-day or on-demand
              • Consider H2RA for maintenance
              • If relapse, resume PPI at prior dose
              • No need for long-term high-dose
              1. Action

                Maintenance Therapy

                Long-term considerations

                • Lowest effective PPI dose
                • Annual attempt to step down
                • No routine labs for PPI monitoring
                • Ca/Vit D for osteoporosis risk
                • Avoid unnecessary long-term use
            2. Action

              PPI Non-Responder

              Further evaluation needed

              • Optimize PPI: timing, compliance, twice daily
              • EGD if not done (rule out EoE, other)
              • Consider pH monitoring off PPI
              • Assess for functional heartburn
              • GI referral recommended
              1. Action

                Reflux Testing

                Ambulatory pH monitoring

                • Wireless pH (Bravo) or impedance-pH
                • Off-PPI testing if diagnosis uncertain
                • On-PPI testing if assessing refractory GERD
                • Establishes reflux-symptom correlation
                1. Action

                  Consider Anti-Reflux Surgery

                  Select patients

                  • Confirmed GERD responding to PPI but preferring no meds
                  • Large hiatal hernia with volume regurgitation
                  • Not for PPI non-responders (poor outcomes)
                  • Requires surgical expertise
      2. Action

        Typical GERD (No Alarms)

        Empiric PPI trial appropriate

        • Classic symptoms: heartburn, regurgitation
        • Symptom response to PPI supports diagnosis
        • No need for confirmatory testing initially

Guideline Source

Clinical Safety Information

Clinical Decision Support — Not a Substitute for Clinical Judgment

Individual patient factors may require deviation from these recommendations.

Known Limitations

  • Does not address Barrett's esophagus surveillance in detail
  • H. pylori testing strategy simplified
  • Surgical referral criteria abbreviated
  • Does not address extra-esophageal GERD manifestations in depth
  • PPI deprescribing approach simplified

Applicable Regions

USAUUKEU

AU: GESA guidelines align with ACG

UK: NICE GERD pathway with step-down approach

US: ACG 2022 guidelines

Version 1Next review: 2028-01-01

Frequently Asked Questions

What is the GERD Evaluation & Management (ACG 2022)?

The GERD Evaluation & Management (ACG 2022) is a management clinical algorithm for Family Medicine. It provides a structured decision tree to guide clinical decision-making, based on ACG Clinical Guideline for GERD.

What guideline is the GERD Evaluation & Management (ACG 2022) based on?

This algorithm is based on ACG Clinical Guideline for GERD (DOI: 10.14309/ajg.0000000000001538).

What are the limitations of the GERD Evaluation & Management (ACG 2022)?

Known limitations include: Does not address Barrett's esophagus surveillance in detail; H. pylori testing strategy simplified; Surgical referral criteria abbreviated; Does not address extra-esophageal GERD manifestations in depth; PPI deprescribing approach simplified. Individual patient factors may require deviation from these recommendations.

Get AI-Powered Analysis Alongside This Algorithm

In AttendMe.ai, the GERD Evaluation & Management (ACG 2022) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.

Try AttendMe Free